anandamide/headache

Lyen an sove nan clipboard la

Chwazi kalite sòt

15 rezilta yo

Acute reduction of anandamide-hydrolase (FAAH) activity is coupled with a reduction of nociceptive pathways facilitation in medication-overuse headache subjects after withdrawal treatment.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE We investigated (1) a possible relationship between the functional activity of the endocannabinoid system and the facilitation of pain processing in migraineurs with medication-overuse headache, and (2) the effect of withdrawal treatment on both. BACKGROUND The endocannabinoid system

Anandamide Is Related to Clinical and Cardiorespiratory Benefits of Aerobic Exercise Training in Migraine Patients: A Randomized Controlled Clinical Trial.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Introduction: Since endocannabinoids have been implicated in migraine pathophysiology, we conducted a randomized, controlled clinical trial to test the effects of a 12-week aerobic exercise intervention on plasma anandamide (AEA) and its relation with clinical, psychological, and

Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Chronic migraine (CM) and medication-overuse headaches (MOH) are well-recognized disabling conditions affecting a significant portion of the headache population attending centers specialized in treating headaches. A dysfunctioning of the serotonergic system has been demonstrated in MOH

Degradation of endocannabinoids in chronic migraine and medication overuse headache.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Chronic migraine (CM) is frequently associated with medication overuse headache (MOH). The endocannabinoid system plays a role in modulating pain including headache and is involved in the common neurobiological mechanism underlying drug addiction and reward system. Anandamide (AEA) and

Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Arachidonylethanolamide (anandamide, AEA) is believed to be the endogenous ligand of the cannabinoid CB(1) and CB(2) receptors. CB(1) receptors have been found localized on fibers in the spinal trigeminal tract and spinal trigeminal nucleus caudalis. Known behavioral effects of anandamide are

Endocannabinoid modulation of inflammatory hyperalgesia in the IFN-α mouse model of depression.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Depression is a well-recognised effect of long-term treatment with interferon-alpha (IFN-α), a widely used treatment for chronic viral hepatitis and malignancy. In addition to the emotional disturbances, high incidences of painful symptoms such as headache and joint pain have also been reported

Post-triptan era for the treatment of acute migraine.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

There now is one realized and several attractive targets for the treatment of acute attacks of migraine that will follow and augment the use of serotonin 5-HT1B/1D receptor agonists, the triptans. Calcitonin gene-related peptide (CGRP) receptor blockade recently has been shown to be an effective

Biochemical changes in endocannabinoid system are expressed in platelets of female but not male migraineurs.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The endogenous cannabinoid anandamide (AEA) plays important roles in modulating pain. Head pain is an almost universal human experience, yet primary headache disorders, such as migraine without aura (MoA) or episodic tension-type headache (ETTH), can represent a serious threat to well-being when

Endocannabinoids in chronic migraine: CSF findings suggest a system failure.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Based on experimental evidence of the antinociceptive action of endocannabinoids and their role in the modulation of trigeminovascular system activation, we hypothesized that the endocannabinoid system may be dysfunctional in chronic migraine (CM). We examined whether the concentrations of

Endocannabinoid System and Migraine Pain: An Update.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The trigeminovascular system (TS) activation and the vasoactive release from trigeminal endings, in proximity of the meningeal vessels, are considered two of the main effector mechanisms of migraine attacks. Several other structures and mediators are involved, however, both upstream and alongside

Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE This study examines the concept of clinical endocannabinoid deficiency (CECD), and the prospect that it could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome, and other functional conditions alleviated by clinical cannabis. METHODS Available literature was

Cannabis for migraine treatment: the once and future prescription? An historical and scientific review.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Cannabis, or Marijuana, has been used for centuries for both symptomatic and prophylactic treatment of migraine. It was highly esteemed as a headache remedy by the most prominent physicians of the age between 1874 and 1942, remaining part of the Western pharmacopoeia for this indication even into

Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Endovanilloids are potential activators of the trigeminovascular nocisensor complex.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND In the dura mater encephali a significant population of trigeminal afferents coexpress the nociceptive ion channel transient receptor potential vanilloid type 1 (TRPV1) receptor and calcitonin gene-related peptide (CGRP). Release of CGRP serves the central transmission of sensory

Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Migraine is a common and disabling neurological disorder that involves activation or the perception of activation of the trigeminovascular system. Cannabinoid (CB) receptors are present in brain and have been suggested to be antinociceptive. Here we determined the effect of cannabinoid receptor

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye